查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1487557

肿瘤学市场的伴随诊断测试（检测技术：蛋白质检测、DNA 检测等；以及生物标记：EGFR、KRAS、HER2、BRAF V600E 等）- 全球产业分析、规模、份额、成长、趋势和预测，2024- 2034

Companion Diagnostic Tests in Oncology Market (Detection Technique: Protein Detection, DNA Detection, and Others; and Biomarker: EGFR, KRAS, HER2, BRAF V600E, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 232 Pages | 商品交期: 2-10个工作天内

价格

肿瘤学市场的伴随诊断测试 - 报告范围

TMR 关于全球肿瘤学伴随诊断测试市场的报告研究了过去以及当前的成长趋势和机会，以获得 2024 年至 2034 年预测期内市场指标的宝贵见解。 2034 年肿瘤学市场诊断测试，以2024 年为基准年，2034 年为预测年。该报告也提供了2024年至2034年全球肿瘤学伴随诊断测试市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解肿瘤市场的伴随诊断测试。

市场概况
2023年市场价值 61 亿美元
2034 年市场价值 170 亿美元
复合年增长率 9.5%

该报告深入研究了肿瘤市场全球伴随诊断测试的竞争格局。肿瘤学市场全球伴随诊断测试中的主要参与者已经确定，并且每位参与者都根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球肿瘤学伴随诊断测试市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2020 - 2034 年全球市场分析与预测

第 5 章：主要见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：透过检测技术

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：按检测技术，2020 - 2034
    • 蛋白质检测
      • 免疫组织化学
    • DNA检测
      • 聚合酶炼式反应 (PCR)
      • 新一代定序 (NGS)
      • 原位杂交
    • 其他的
  • 市场吸引力：透过检测技术

第 7 章：全球市场分析与预测：按 Biomarker

  • 简介和定义
  • 主要发现/进展
  • 市值预测：依 Biomarker 划分，2020 - 2034 年
    • 表皮生长因子受体
    • 克拉斯
    • HER2
    • 布拉夫V600E
    • 其他的
    • 7.4 市场吸引力：依生物标誌物

第 8 章：全球市场分析与预测：按癌症类型

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：按癌症类型，2020 - 2034
    • 乳癌
    • 肺癌
    • 大肠直肠癌
    • 肝癌
    • 黑色素瘤
    • 其他的
  • 市场吸引力：按癌症类型

第 9 章：全球市场分析与预测：按最终用户

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：按最终用户，2020 - 2034
    • 医院
    • 专科诊所
    • 诊断实验室
    • 其他的
  • 市场吸引力：按最终用户划分

第 10 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2020 - 2034
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力：按地区

第 11 章：北美市场分析与预测

第 12 章：欧洲市场分析与预测

第 13 章：亚太市场分析与预测

第 14 章：拉丁美洲市场分析与预测

第 15 章：中东和非洲市场分析与预测

第16章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司分类（2023）
  • 公司简介
    • Abbott
    • F. Hoffmann-LA Roche AG
    • Genomic Health, Inc.
    • QIAGEN
    • Agilent Technologies, Inc.
    • AGENDIA NV
    • bioMerieux SA
    • Illumina, Inc.
    • Siemens Healthineers
    • Thermo Fisher Scientific Inc.
    • BioGenex
Product Code: TMRGL4684

Companion Diagnostic Tests in Oncology Market - Scope of Report

TMR's report on the global companion diagnostic tests in oncology market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global companion diagnostic tests in oncology market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global companion diagnostic tests in oncology market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the companion diagnostic tests in oncology market.

Market Snapshot
Market Value in 2023US$ 6.1 Bn
Market Value in 2034US$ 17 Bn
CAGR9.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global companion diagnostic tests in oncology market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global companion diagnostic tests in oncology market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global companion diagnostic tests in oncology market.

The report delves into the competitive landscape of the global companion diagnostic tests in oncology market. Key players operating in the global companion diagnostic tests in oncology market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global companion diagnostic tests in oncology market profiled in this report.

Key Questions Answered in Global companion diagnostic tests in oncology Market Report:

  • What is the sales/revenue generated by companion diagnostic tests in oncology across all regions during the forecast period?
  • What are the opportunities in the global companion diagnostic tests in oncology market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Companion Diagnostic Tests in Oncology Market - Research Objectives and Research Approach

The comprehensive report on the global companion diagnostic tests in oncology market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global companion diagnostic tests in oncology market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global companion diagnostic tests in oncology market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Companion Diagnostic Tests in Oncology Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, 2020 - 2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Detection Technique

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Detection Technique, 2020 - 2034
    • 6.3.1. Protein Detection
      • 6.3.1.1. Immunohistochemistry
    • 6.3.2. DNA Detection
      • 6.3.2.1. Polymerase Chain Reaction (PCR)
      • 6.3.2.2. Next-generation Sequencing (NGS)
      • 6.3.2.3. In Situ Hybridization
    • 6.3.3. Others
  • 6.4. Market Attractiveness, by Detection Technique

7. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Biomarker

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Biomarker, 2020 - 2034
    • 7.3.1. EGFR
    • 7.3.2. KRAS
    • 7.3.3. HER2
    • 7.3.4. BRAF V600E
    • 7.3.5. Others
    • 7.3.6. 7.4 Market Attractiveness, by Biomarker

8. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Cancer Type

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Cancer Type, 2020 - 2034
    • 8.3.1. Breast Cancer
    • 8.3.2. Lung Cancer
    • 8.3.3. Colorectal Cancer
    • 8.3.4. Liver Cancer
    • 8.3.5. Melanoma
    • 8.3.6. Others
  • 8.4. Market Attractiveness, by Cancer Type

9. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by End-user

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2020 - 2034
    • 9.3.1. Hospitals
    • 9.3.2. Specialty Clinics
    • 9.3.3. Diagnostic Labs
    • 9.3.4. Others
  • 9.4. Market Attractiveness, by End-user

10. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020 - 2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Companion Diagnostic Tests in Oncology Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Detection Technique, 2020 - 2034
    • 11.2.1. Protein Detection
      • 11.2.1.1. Immunohistochemistry
    • 11.2.2. DNA Detection
      • 11.2.2.1. Polymerase Chain Reaction (PCR)
      • 11.2.2.2. Next-generation Sequencing (NGS)
      • 11.2.2.3. In Situ Hybridization
    • 11.2.3. Others
  • 11.3. Market Attractiveness, by Detection Technique
  • 11.4. Market Value Forecast, by Biomarker, 2020 - 2034
    • 11.4.1. EGFR
    • 11.4.2. KRAS
    • 11.4.3. HER2
    • 11.4.4. BRAF V600E
    • 11.4.5. Others
  • 11.5. Market Attractiveness, by Biomarker
  • 11.6. Market Value Forecast, by Cancer Type, 2020 - 2034
    • 11.6.1. Breast Cancer
    • 11.6.2. Lung Cancer
    • 11.6.3. Colorectal Cancer
    • 11.6.4. Liver Cancer
    • 11.6.5. Melanoma
    • 11.6.6. Others
  • 11.7. Market Attractiveness, by Cancer Type
  • 11.8. Market Value Forecast, by End-user, 2020 - 2034
    • 11.8.1. Hospitals
    • 11.8.2. Specialty Clinics
    • 11.8.3. Diagnostic Labs
    • 11.8.4. Others
  • 11.9. Market Attractiveness, by End-user
  • 11.10. Market Value Forecast, by Country, 2020 - 2034
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Detection Technique
    • 11.11.2. By Biomarker
    • 11.11.3. By Cancer Type
    • 11.11.4. By End-user
    • 11.11.5. By Country

12. Europe Companion Diagnostic Tests in Oncology Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Detection Technique, 2020 - 2034
    • 12.2.1. Protein Detection
      • 12.2.1.1. Immunohistochemistry
    • 12.2.2. DNA Detection
      • 12.2.2.1. Polymerase Chain Reaction (PCR)
      • 12.2.2.2. Next-generation Sequencing (NGS)
      • 12.2.2.3. In Situ Hybridization
    • 12.2.3. Others
  • 12.3. Market Attractiveness, by Detection Technique
  • 12.4. Market Value Forecast, by Biomarker, 2020 - 2034
    • 12.4.1. EGFR
    • 12.4.2. KRAS
    • 12.4.3. HER2
    • 12.4.4. BRAF V600E
    • 12.4.5. Others
  • 12.5. Market Attractiveness, by Biomarker
  • 12.6. Market Value Forecast, by Cancer Type, 2020 - 2034
    • 12.6.1. Breast Cancer
    • 12.6.2. Lung Cancer
    • 12.6.3. Colorectal Cancer
    • 12.6.4. Liver Cancer
    • 12.6.5. Melanoma
    • 12.6.6. Others
  • 12.7. Market Attractiveness, by Cancer Type
  • 12.8. Market Value Forecast, by End-user, 2020 - 2034
    • 12.8.1. Hospitals
    • 12.8.2. Specialty Clinics
    • 12.8.3. Diagnostic Labs
    • 12.8.4. Others
  • 12.9. Market Attractiveness, by End-user
  • 12.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Detection Technique
    • 12.11.2. By Biomarker
    • 12.11.3. By Cancer Type
    • 12.11.4. By End-user
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Companion Diagnostic Tests in Oncology Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Detection Technique, 2020 - 2034
    • 13.2.1. Protein Detection
      • 13.2.1.1. Immunohistochemistry
    • 13.2.2. DNA Detection
      • 13.2.2.1. Polymerase Chain Reaction (PCR)
      • 13.2.2.2. Next-generation Sequencing (NGS)
      • 13.2.2.3. In Situ Hybridization
    • 13.2.3. Others
  • 13.3. Market Attractiveness, by Detection Technique
  • 13.4. Market Value Forecast, by Biomarker, 2020 - 2034
    • 13.4.1. EGFR
    • 13.4.2. KRAS
    • 13.4.3. HER2
    • 13.4.4. BRAF V600E
    • 13.4.5. Others
  • 13.5. Market Attractiveness, by Biomarker
  • 13.6. Market Value Forecast, by Cancer Type, 2020 - 2034
    • 13.6.1. Breast Cancer
    • 13.6.2. Lung Cancer
    • 13.6.3. Colorectal Cancer
    • 13.6.4. Liver Cancer
    • 13.6.5. Melanoma
    • 13.6.6. Others
  • 13.7. Market Attractiveness, by Cancer Type
  • 13.8. Market Value Forecast, by End-user, 2020 - 2034
    • 13.8.1. Hospitals
    • 13.8.2. Specialty Clinics
    • 13.8.3. Diagnostic Labs
    • 13.8.4. Others
  • 13.9. Market Attractiveness, by End-user
  • 13.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Detection Technique
    • 13.11.2. By Biomarker
    • 13.11.3. By Cancer Type
    • 13.11.4. By End-user
    • 13.11.5. By Country/Sub-region

14. Latin America Companion Diagnostic Tests in Oncology Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Detection Technique, 2020 - 2034
    • 14.2.1. Protein Detection
      • 14.2.1.1. Immunohistochemistry
    • 14.2.2. DNA Detection
      • 14.2.2.1. Polymerase Chain Reaction (PCR)
      • 14.2.2.2. Next-generation Sequencing (NGS)
      • 14.2.2.3. In Situ Hybridization
    • 14.2.3. Others
  • 14.3. Market Attractiveness, by Detection Technique
  • 14.4. Market Value Forecast, by Biomarker, 2020 - 2034
    • 14.4.1. EGFR
    • 14.4.2. KRAS
    • 14.4.3. HER2
    • 14.4.4. BRAF V600E
    • 14.4.5. Others
  • 14.5. Market Attractiveness, by Biomarker
  • 14.6. Market Value Forecast, by Cancer Type, 2020 - 2034
    • 14.6.1. Breast Cancer
    • 14.6.2. Lung Cancer
    • 14.6.3. Colorectal Cancer
    • 14.6.4. Liver Cancer
    • 14.6.5. Melanoma
    • 14.6.6. Others
  • 14.7. Market Attractiveness, by Cancer Type
  • 14.8. Market Value Forecast, by End-user, 2020 - 2034
    • 14.8.1. Hospitals
    • 14.8.2. Specialty Clinics
    • 14.8.3. Diagnostic Labs
    • 14.8.4. Others
  • 14.9. Market Attractiveness, by End-user
  • 14.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Detection Technique
    • 14.11.2. By Biomarker
    • 14.11.3. By Cancer Type
    • 14.11.4. By End-user
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Companion Diagnostic Tests in Oncology Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Detection Technique, 2020 - 2034
    • 15.2.1. Protein Detection
      • 15.2.1.1. Immunohistochemistry
    • 15.2.2. DNA Detection
      • 15.2.2.1. Polymerase Chain Reaction (PCR)
      • 15.2.2.2. Next-generation Sequencing (NGS)
      • 15.2.2.3. In Situ Hybridization
    • 15.2.3. Others
  • 15.3. Market Attractiveness, by Detection Technique
  • 15.4. Market Value Forecast, by Biomarker, 2020 - 2034
    • 15.4.1. EGFR
    • 15.4.2. KRAS
    • 15.4.3. HER2
    • 15.4.4. BRAF V600E
    • 15.4.5. Others
  • 15.5. Market Attractiveness, by Biomarker
  • 15.6. Market Value Forecast, by Cancer Type, 2020 - 2034
    • 15.6.1. Breast Cancer
    • 15.6.2. Lung Cancer
    • 15.6.3. Colorectal Cancer
    • 15.6.4. Liver Cancer
    • 15.6.5. Melanoma
    • 15.6.6. Others
  • 15.7. Market Attractiveness, by Cancer Type
  • 15.8. Market Value Forecast, by End-user, 2020 - 2034
    • 15.8.1. Hospitals
    • 15.8.2. Specialty Clinics
    • 15.8.3. Diagnostic Labs
    • 15.8.4. Others
  • 15.9. Market Attractiveness, by End-user
  • 15.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Detection Technique
    • 15.11.2. By Biomarker
    • 15.11.3. By Cancer Type
    • 15.11.4. By End-user
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. Abbott
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. F. Hoffmann-LA Roche AG
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Genomic Health, Inc.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. QIAGEN
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Agilent Technologies, Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. AGENDIA N.V.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. bioMerieux SA
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Illumina, Inc.
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Siemens Healthineers
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Thermo Fisher Scientific Inc.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. BioGenex
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview

List of Tables

  • Table 01: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
  • Table 02: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
  • Table 03: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
  • Table 04: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
  • Table 05: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Region, 2020 - 2034
  • Table 06: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country, 2020 - 2034
  • Table 07: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
  • Table 08: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
  • Table 9: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
  • Table 10: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
  • Table 11: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034
  • Table 12: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
  • Table 13: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
  • Table 14: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
  • Table 15: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
  • Table 16: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034
  • Table 17: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
  • Table 18: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
  • Table 19: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
  • Table 20: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
  • Table 21: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034
  • Table 22: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
  • Table 23: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
  • Table 24: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
  • Table 25: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
  • Table 26: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034
  • Table 27: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
  • Table 28: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
  • Table 29: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
  • Table 30: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034

List of Figures

  • Figure 01: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million), by Region, 2023 - 2034
  • Figure 02: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Detection Technique, 2023
  • Figure 03: Global Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2023
  • Figure 04: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Biomarker, 2023
  • Figure 05: Global Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2023
  • Figure 06: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Cancer Type, 2023
  • Figure 07: Global Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2023
  • Figure 08: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by End-user, 2023
  • Figure 09: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2023
  • Figure 10: Global Companion Diagnostic Tests in Oncology Market Value Share, by Region, 2023
  • Figure 11: Global Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast, 2020 - 2034
  • Figure 12: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
  • Figure 13: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
  • Figure 14: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
  • Figure 15: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
  • Figure 16: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
  • Figure 17: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
  • Figure 18: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by End-user, 2023
  • Figure 19: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2023
  • Figure 20: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Region, 2023 - 2034
  • Figure 21: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Region, 2024 - 2034
  • Figure 22: North America Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
  • Figure 23: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country, 2024 - 2034
  • Figure 24: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country, 2023 - 2034
  • Figure 25: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
  • Figure 26: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
  • Figure 27: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
  • Figure 28: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
  • Figure 29: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
  • Figure 30: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
  • Figure 31: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
  • Figure 32: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034
  • Figure 33: Europe Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
  • Figure 34: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034
  • Figure 35: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034
  • Figure 36: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
  • Figure 37: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
  • Figure 38: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
  • Figure 39: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
  • Figure 40: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
  • Figure 41: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
  • Figure 42: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
  • Figure 43: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034
  • Figure 44: Asia Pacific Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
  • Figure 45: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034
  • Figure 46: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034
  • Figure 47: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
  • Figure 48: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
  • Figure 49: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
  • Figure 50: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
  • Figure 51: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
  • Figure 52: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
  • Figure 53: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
  • Figure 54: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2023-2034
  • Figure 55: Latin America Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
  • Figure 56: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034
  • Figure 57: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034
  • Figure 58: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
  • Figure 59: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
  • Figure 60: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
  • Figure 61: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
  • Figure 62: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
  • Figure 63: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
  • Figure 64: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
  • Figure 65: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034
  • Figure 66: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
  • Figure 67: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034
  • Figure 68: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034
  • Figure 69: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
  • Figure 70: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
  • Figure 71: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
  • Figure 72: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
  • Figure 73: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
  • Figure 74: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
  • Figure 75: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
  • Figure 76: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034